References

1. Goff SP. Retroviridae: The retroviruses and their replication. In: Knipe DM, Howley PM, Eds. Fields Virology. 4th ed.. Philadelphia: Lippincott Williams & Wilkins, 2001: 1871-1939.

2. Yee JK. Retroviral vectors. In: Friedmann T, Ed. The Development of Human Gene Therapy. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1999:21-46.

3. Freed T, Martin A. HIVs and their replication. In: Knipe DM, Howley PM, Eds. Fields Virology. 4th ed.. Philadelphia: Lippincott Williams & Wilkins, 2001:1971-2041.

4. Temin HM. Safety consideration in somatic gene therapy of human disease with retrovirus vectors. Hum Gene Ther 1990; 1:111-123.

5. Vanin EF, Kaloss M, Broscius C, Nienhuis AW. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J Virol 1994; 68: 4241-4250.

6. Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 1992; 11:3053-3058.

7. Terwilliger EF, Godin B, Sodroski JG, Haseltine WA. Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme. Proc Natl Acad Sci USA 1989; 86: 3857-3861.

8. Lever A, Gottlinger H, Haseltine W, Sodroski J. Identification of a sequence required for efficient packaging of human immu nodeficiency virus type 1 RNA into virions. J Virol 1989; 63: 4085-4087.

9. Page KA, Landau NR, Littman DR. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol 1990; 64:5270-5276.

10. Emi N, Friedmann T, Yee JK. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J Virol 1991; 65:1202-1207.

11. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped ret-roviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90:8033-8037.

12. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272:263-267.

13. Desrosiers R. Nonhuman lentiviruses. In: Knipe DM, Howley PM, Eds. Fields Virology. 4th ed.: Philadelphia: Lippincott William & Wilkins, 2001:2095-2121..

14. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15:871-875.

15. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72:8463-8471.

16. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72:811-816.

17. Gasmi M, Glynn J, Jin MJ, Jolly DJ, Yee JK, Chen ST. Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J Virol 1999; 73:1828-1834.

18. Ikeda Y, Collins MKL, Radcliffe PA, Mitrophanous KA, Ta-keuchi Y. Gene transduction efficiency in cells of different species by HIV and EIAV vectors. Gene Ther 2002; 9: 932-938.

19. O'Rourke JP, Newbound GC, Kohn DB, Olsen JC, Bunnell BA. Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors. J Virol 2002; 76:1510-1515.

20. Emerman M, Malim MH. HIV-1 regulator/accessory genes: Keys to unraveling viral and host cell biology. Science 1998; 280:1880-1884.

21. Stevenson M. Molecular biology of lentivirus-mediated gene transfer. Curr Top Microbiol Immunol 2002; 261:1-30.

22. Curran MA, Nolan GP. Nonprimate lentiviral vectors. Curr Top Micobiol Immunol 2002; 261:76-105.

23. Chatterji U, Paserval A, Elder JH. Feline immunodeficiency virus OrfA is distinct from other lentivirus transactivators. J Virol 2002; 76:9624-9634.

24. Farnet CM, Haseltine WA. Determination of viral proteins in the human immunodeficiency virus type 1 preintegration complex. J Virol 1991; 65:1910-1915.

25. Fassati A, Goff SP. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 2001; 75:3626-3635.

26. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhu-bel A, Splitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993; 365: 666-669.

27. Von Schwedler U, Kornbluth RS, Trono D. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macro-

phages and quiescent T lymphocytes. Proc Natl Acad Sci USA 1994; 91:6992-6996.

Gallay P, Hope T, Chin D, Trono D. HIV-1 infection of nondi-viding cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci USA 1997; 94:9825-9830.

Heinzinger NK, Bukrinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994;91:7311-7315.

Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear import is mediated by central DNA flap. Cell 2000; 101:173-185. Limon A, Devroe E, Lu R, Ghory HZ, Silver PA, Engelman A. Nuclear localization of human immunodeficiency virus type 1 preintegration complexes (PICs): V165A and R166A are pleiotropic integrase mutants primarily defective for integration, not PIC nuclear import. J Virol 2002; 76:10598-10607. Deminie CA, Emerman M. Functional exchange of an oncore-trovirus and a lentivirus matrix protein. J Virol 1994; 68: 4442-4449.

Dvorin JD, Bell P, Maul GG, Yamashita M, Emerman M, Malim MH. Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol 2002; 76:12087-12096. Park F, Ohashi K, Chiu W, Naldini L, Kay MA. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat Genet 2000; 24:49-52.

Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17:314-317. Miyake K, Suzuki N, Matsuoka H, Tohyama T, Shimada T. Stable integration of human immunodeficiency virus-based retroviral vectors into the chromosomes of nondividing cells. Hum Gene Ther 1998; 9:467-475.

Uchida N, Sutton RE, Friera AM, He D, Reitsma MJ, Chang WC, Veres G, Scollay R, Weissman IL. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci USA 1998; 95:11939-11944. Ott DE, Coren LV, Sowder RC, Adams J, Schubert U. Retrovi-ruses have differing requirements for proteasome function in the budding process. J Virol 2003; 77:3384-3393. Patnaik A, Chau V, Li F, Monteclaro RC, Wills JW. Budding of equine infectious anemia virus is insensitive to proteasome inhibitors. J Virol 2002; 76:2641-2647. Clever JL, Miranda D, Parslow TG. RNA structure and packaging signals in the 5' leader region of the human immunodeficiency virus type 1 genome. J Virol 2002; 76:12381-12387. Kaye JF, Lever AM. Trans-acting proteins involved in RNA encapsidation and viral assembly in human immunodeficiency virus type 1. J Virol 1996; 70:880-886. Wang SW, Aldovini A. RNA incorporation is critical for ret-roviral particle integrity after cell membrane assembly of Gag complexes. J Virol 2002; 76:11853-11865. McBride MS, Panganiban AT. The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures. J Virol 1996; 70: 2963-2973.

Kaye JF, Lever AM. Human immunodeficiency virus type 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation. J Virol 1999; 73: 3023-3031.

45. Negre D, Mangeot PE, Duisit G, Blanchard S, Vidalain PO, Leissner P, Winter AJ, Rabourding-Combe C, Mehtali M, Moullier P, Darlix JL, Cosset FL. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 2000; 7:1613-1623.

46. Mitrophanous KA, Yoon S, Rohll JB, Patil D, Wilkes FJ, Kim VN, Kingsman SM, Mazarakis ND. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 1999; 6:1808-1818.

47. Johnston JC, Gasmi M, Lim LE, Elder JH, Yee JK, Jolly DJ, Campbell KP, Davidson BL, Sauter SL. Minimum requirements for efficient transduction of dividing and nondividing cells by feline virus vectors. J Virol 1999; 73:4991-5000.

48. Kembler I, Barraza R, Poeschla EM. Mapping the encapsida-tion determinants of feline immunodeficiency virus. J Virol 2002; 76:11889-11903.

49. Molina RP, Matukonis M, Paszkiet B, Zhang J, Kaleko M, Luo T. Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector. J Virol 2002; 304:10-23.

50. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mi-trophanous KA. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-opti-mized HIV-1 gag-pol gene. J Virol 2000; 74:4839-4852.

51. Wagner R, Graf M, Bieler K, Wolf H, Grunwald T, Foley P, Uberla K. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: Implications for the safety of lentiviral vectors. Hum Gene Ther 2000; 11:2403-2413.

52. Matukonis M, Li M, Molina RP, Paszkiet B, Kaleko M, Luo T. Development of second- and third-generation bovine immunodeficiency virus-based gene transfer systems. Hum Gene Ther 2002; 13:1293-1303.

53. Pandya S, Boris-Lawrie K, Leung NJ, Akkina R, Planelles V. Development of a Rev-independent, minimal simian immunodeficiency virus-derived vector system. Hum Gene Ther 2001; 12:847-857.

54. Dardalhon V, Herpes B, Noraz N, Pflumio F, Guetard D, Lev-eau C, Dubart-Kupperschmitt A, Charneau P, Taylor N. Len-tivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther 2001; 8:190-198.

55. Barry SC, Harder B, Brzezinski M, Flint LY, Seppen J, Os-borne WR. Lentivirus vectors encoding both central polypur-ine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther 2001; 12:1103-1108.

56. Bray M, Prasad S, Dubay JW, Hunter E, Jeang KT, Rekosh D, Hammarskjold ML. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci USA 1994; 91:1256-1260.

57. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73:2886-2892.

58. Mazarakis ND, Azzouz M, Rohll JB, Ellard FM, Wilkes FJ, Olsen AL, Carter EE, Barber RD, Baban DF, Kingsman SM, Kingsman AJ, O'Malley K, Mitrophanous KA. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001; 10:2109-2121.

59. Desmaris N, Bosch A, Salaun C, Petit C, Prevost MC, Tordo N, Perrin P, Schwartz O, de Rocquigny H, Heard JM. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol Ther 2001; 4: 149-156.

60. Watson DJ, KobingerGP, Passini MA, Wilson JM, Wolfe JH. 77. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther 2002; 5:528-537. 78.

61. Kobayashi M, Iida A, Ueda Y, Hasegawa M. Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J Virol 2003; 77:2607-2614. 79.

62. Kowolik CM, Yee JK. Preferential transduction of human hep-atocytes with lentiviral vectors pseudotyped by Sendai virus F protein. Mol Ther 2002; 5:762-769.

63. Kang Y, Stein CS, Heth JA, Sinn PL, Penisten AK, Staber PD, Ratliff KL, Shen H, Barker CK, Martins I, Sharkey CM, Sanders DA, McCray PB, Davidson BL. In vivo gene transfer 80. using a nonprimate lentiviral vector pseudotyped with Ross

River virus glycoproteins. J Virol 2002; 76:9378-9388. 81.

64. Sutton RE, Littman DR. Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system. J Virol 1996; 70:7322-7326. 82.

65. Duisit G, Conrath H, Saleun S, Folliot S, Provost N, Cossett FL, Sandrin V, Moullier P, Rolling F. Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive trans- 83. duction of retinal pigmented epithelium in rat. Mol Ther 2002; 6:446-454.

66. An DS, Xie YM, Chen IS. Envelope gene of the human endogenous retrovirus HERV-W encodes a functional retrovirus en- 84. velope. J Virol 2001; 75:3488-3489.

67. Beyer WR, Westphal M, Ostertag W, von Laer D. Oncoretrov-irus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: Generation, concentra- 85. tion, and broad host range. J Virol 2002; 76:1488-1495.

68. Lewis BC, Chinnasamy N, Morgan RA, Varmus HE. Development of an avian leucosis-sarcoma virus subgroup A pseu- 86. dotyped lentiviral vector. J Virol 2001; 75:9339-9344.

69. Janssens W, Marinee KL, Naldini L, Follenzi A, Collen D, Saint-Remy JM, Vandendriessche T. Efficiency of onco-ret-roviral and tentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent. Hum Gene 87. Ther 2003; 14:263-276.

70. Sandrin V, Boson B, Salmon P, Gay W, Negre D, Le Grand R, Trono D, Cosset FL. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased sta- 88. bility in sera and augmented transduction of primary lymphocytes and CD34 + cells derived from human and nonhuman primates. Blood 2002; 100:823-832.

71. Pickl WF, Pimentel-Muinos FX, Seed B. Lipid rafts and pseu- 89. dotyping. J Virol 2001; 75:7175-7183.

72. Saifuddin M, Crnich C, Long T, Saarloos MN, Spear GT. Transfer of host T-cell membrane HLA-DR and CD25 to target cells by human retroviruses. J Acquir Immune Defic Syndr 90. Hum Retroviral 1998; 17:196-202.

73. DePolo NJ, Reed JD, Sheridan PL, Townsend K, Sauter SL, Jolly DJ, Dubensky T. VSV-G pseudotypoed lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther 2000; 2:218-222. 91.

74. Follenzi A, Sabatino G, Lombardo A, Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13: 243-260.

75. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998; 72:8150-8157. 92.

76. Owens CM, Yang PC, Gottlinger H, Sodroski J. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, post-entry replication blocks in simian cells. J Virol 2003; 77:726-731.

Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J 2003; 22:385-394.

Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. PNAS 2003; 100: 1298-1303.

Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of parkinson's disease. Science 2000; 290:767-771. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther 1998; 5:1481-1487. Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM. A packaging cell line for lentivirus vectors. J Virol 1999; 73: 576-584.

Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer self-inactivating len-tiviral vectors. Mol Ther 2001; 3:97-104. Sparacio S, Pfeiffer T, Schaal H, Bosch V. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol Ther 2001; 3:602-612.

Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song J, Radeke R, Bukovsky A, Consiglio A, Naldini L. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 2001; 12:981-997. Klages N, Zufferey R, Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther 2000; 2:170-176.

Chen ST, Iida A, Guo L, Friedmann T, Yee JK. Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible systems. Proc Natl Acad Sci USA 1996; 93:10057-10062.

Kuate S, Wagner R, Uberla K. Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. J Gene Med 2002; 4:347-355.

Shimada T, Fujil H, Mitsuya H, Nienhuis AW. Targeted and highly efficient gene transfer into CD4 + cells by a recombinant human immunodeficiency virus retroviral vector. J Clin Invest 1991; 88:1043-1047.

Carroll R, Lin JT, Dacquel EJ, Mosca JD, Burke DS, St. Louis DC. A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. J Virol 1994; 68:6047-6051.

Srinivasakumar N, Chazal N, Helga-Maria C, Prasad S, Ham-marskjold ML, Rekosh D. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 1997; 71:5841-5848.

Sheridan PL, Bodner M, Lynn A, Phuong TK, DePolo NJ, de la Vega DJ, O'Dea J, Nguyen K, McCormack JE, Driver DA, Townsend K, Ibanez CE, Sajjadi NC, Greengard JS, Moore MD, Respess J, Chang SMW, Dubensky TW, Jolly DJ, Sauter SL. Generation of retroviral packaging and producer cell lines for large-scale vector production: Improved safety and high titer. Mol Ther 2000; 2:262-275.

Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90:8392-8396.

Laughlin MA, Zeicchner S, Kolson D, Alwine JC, Seshamma T, Pomerantz RJ, Gonzalez-Scarano F. Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 1993; 196:496-505. Soneoka F, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23:628-633. Coleman JE, Huentelman MJ, Kasparov S, Metcalfe BL, Paton JRF, Katovich MJ, Semple-Rowland SL, Raizada MK. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221-228.

Rohll JB, Mitrophanous KA, Martin-Rendon E, Ellard FM, Radcliffe PA, Mazarakis ND, Kingsman SM. Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol 2002; 346:466-500. Schilz AJ, Kuhlcke K, Fauser AA, Eckert HG. Optimization of retroviral vector generation for clinical application. J Gene Med 2001; 3:427-436.

Scherr M, Batmer K, Eder M, Schule S, Hohenberg H, Ganser A, Grez M, Blomer U. Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther 2002; 9:1708-1714.

Zhang B, Xia HQ, Cleghorn G, Gobe G, West M, Wei MQ. A highly efficient and consistent method for harvesting large volumes of high-titer lentiviral vectors. Gene Ther 2001; 8: 1745-1751.

Zufferey R. Production of lentiviral vectors. Curr Top Micro-biol Immunol 2002; 261:107-121.

Dulbecco R. Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc Natl Acad Sci USA 1952; 38:747-752.

Forestell SP, Dando JS, Bohnlein E, Rigg RJ. Improved detection of replication-competent retrovirus. J Virol 1996; 60: 171-178.

Martin-Rendon E, White LJ, Olsen A, Mitrophanous KA, Ma-zarakis ND. New methods to titrate EIAV-based lentiviral vectors. Mol Ther 2002; 5:566-570.

Sastry L, Johnson T, Hobson MJ, Smucker B, Cornetta K. Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods. Gene Ther 2002; 9:1155-1162. Connolly JB. Lentiviruses in gene therapy clinical research. Gene Ther 2002; 9:1730-1734.

Naldini L, Blomer U, Gage FH, Trono D, Verma IM. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93:11382-11388. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage F. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71:6641-6649. Kordower JH, Bloch J, Ma SY, Chu Y, Palfi S, Roitberg BZ, Emborg M, Hantraye P, Deglon N, Aebischer P. Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 1999; 160:1-16.

Mitrophanous KA, Yoon S, Rohll JB, Patil D, Wailkes FJ, Kim VN, Kingsman SM, Kingsman AJ, Mazarakis ND. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 1999; 6:1808-1818. Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B, Debyser Z. Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum Gene Ther 2002; 13:841-853.

Deglon N, Aebischer P. Lentiviruses as vectors for CNS disease. Curr Top Microbiol Immunol 2002; 261:191-209.

112. Brooks AI, Stein CS, Hughes SM, Heth J, McCray PM, Sauter SL, Johnston JC, Cory-Slechta DA, Federoff HJ, Davidson BL. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA 2002; 99:6216-6221.

113. Bosch A, Perret E, Desmaris N, Trono D, Heard JM. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther 2000; 11:1139-1150.

114. Regulier E, De Almeida LP, Sommer B, Aebischer P, Deglon N. Dose-dependent neuroprotective effect of ciliary neuro-trophic factor delivered via tetracycline-regulated lentiviral vector in the quinolinic acid rat model of Huntington's disease. Hum Gene Ther 2002; 13:1981-1990.

115. Azzouz M, Martin-Rendon E, Barber RD, Mitrophanous KA, Carter EE, Rohll JB, Kingsman SM, Kingsman AJ, Mazarakis ND. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 2002; 22:10302-10312.

116. Kordower JH, Bloch J, Ma SY, Chu Y, Palfi S, Roitberg BZ, Emborg M, Hantraye P, Deglon D, Aebischer P. Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 1999; 160:1-16.

117. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bu-jard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268:1766-1769.

118. Kafri T, van Praag H, Gage FH, Verma IM. Lentiviral vectors: Regulated gene expression. Mol Ther 2000; 1:516-521.

119. Ye X, rivera VM, Zoltick P, Cerasoli F, Schnell MA, Gao GP, Hughes JV, Gilman M, Wilson JM. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999; 283:88-91.

120. Wang Y, DeMayo FJ, Tsai SY, O'Malley BW. Ligand-induci-ble and liver-specific target gene expression in transgenic mice. Nat Biotechnol 1997; 15:239-243.

121. Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based len-tiviral vector. Proc Natl Acad Sci USA 1997; 94: 10319-10323.

122. Derksen TA, Sauter SL, Davidson BL. Feline immunodeficiency virus vectors. Gene transfer to mouse retina following intravitreal injection. J Gene Med 2002; 4:463-469.

123. Lotery AJ, Derksen TA, Russell SR, Mullins RF, Sauter S, Affatigato LM, Stone EM, Davidson BL. Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors. Hum Gene Ther 2002; 13:689-696.

124. Takahashi K, Luo T, Saishin Y, Saishin Y, Sung J, Hackett S, Brazzell RK, Kaleko M, Campochiaro PA. Sustained trans-duction of ocular cells with a bovine immunodeficiency viral vector. Hum Gene Ther 2002; 13:1305-1316.

125. Van Adel BA, Kostic C, Deglon N, Ball AK, Arsenijevic Y. Delivery of ciliary neurotropic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time. Hum Gene Ther 2003; 14:103-115.

126. Mori K, Gehlbach P, Ando A, Mc Vey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43:2428-2434.

127. Pan D, Gunther R, Duan W, Wendell S, Kaemmerer W, Kafri T, Verma IM, Whitley CB. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration of in vivo transduction of bone marrow. Mol Ther 2002; 6:19-29.

128. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset FL, Russell SJ. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. 141. Gene Ther 2001; 8:1456-1463.

129. Park F, Kay MA. Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo. Mol Ther 2001; 4:164-173.

130. Ohashi K, Park F, Kay MA. Role of hepatocyte direct hyper- 142. plasia in lentivirus-mediated liver transduction in vivo. Hum Gene Ther 2002; 13:653-663.

131. Tsui LV, Kelley M, Zayek N, Rojas V, Ho K, Ge Y, Moska- 143. lenko M, Modensire J, Davis J, Roey MV, Dull T, McArthur JG. Production of human clotting factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Bio-technol 2002; 20:53-57. 144.

132. Nguyen TH, Oberholzer J, Birraux J, Majno P, Morel P, Trono D. Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol Ther 2002; 6:199-209.

133. Piancibello W, Bruno S, Sanavio F, Droetto S, Gunetti M, 145. Ailles L, de Sio FS, Viate A, Gammaitoni L, Lombardo A, Naldini L, Aglietta M. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage. Blood 2002; 100: 4391-4400. 146.

134. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of human CD34 + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 147. 1999; 283:682-686.

135. Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T, Kole R. High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery 148. of an antisense snRNA. Blood 2003; 101:104-111.

136. Imren S, Payen E, Westerman KA, Pawliuk R, Fabry ME, Eaves CJ, Cavilla B, Wadsworth LD, Beuzard Y, Bouhassira 149. EE, Rusell R, London IM, Nagel RL, Leboulch P, Humphries

RK. Permanent and panerythroid correction of murine B tha- 150. lassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci USA 2002; 99:14380-14385.

137. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe T, 151. Bouhassira EE, Acharya SA, Ellis J, London IM, Eaves CJ, Humphries RK, Beuzard Y, Nagel RL, Leboulch P. Correction of sickle cell disease in transgenic mouse models by gene 152. therapy. Science 2001; 294:2368-2371.

138. Roesler J, Brenner S, Bukovsky AA, Whiting-Theobald N, Dull T, Kelly M, Civin CI, Malech HL. Third-generation, self- 153. inactivating gp91phox lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized 154. CD34 + cells from patients with X-linked chronic granulomatous disease. Blood 2002; 100:4381-4390. 155.

139. Poeschla E, Corbeau P, Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996;93:11395-11399. 156.

140. Dropulic B, Hermankova M, Pitha PM. A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replica tion and spread. Proc Natl Acad Sci USA 1996; 93: 11103-11108.

Mautino MR, Morgan RA. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA. Hum Gene Ther 2002; 13: 1027-1037.

Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006-1010.

Qin XP, An DS, Chen ISY, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100:183-188.

Bovia F, Salmon P, Mathes T, Nguyen KH, Wermer-Favre C, Barnet M, Nagy M, Leuba F, Arrighi JF, Piguet V, Trono D, Zubler RH. Efficient transduction of primary human B lymphocytes and nondividing myeloma B cells with HIV-1-de-rived lentiviral vectors. Blood 2003; 101:1727-1733. Obaru K, Fujii S, Matsushita S, Shimada T, Takatsuki K. Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1. Hum Gene Ther 1996; 7: 2203-2208.

Johnson LG, Olsen JC, Naldini L, Boucher RC. Pseudotyped human lentiviral vector-meadiated gene transfer to airway epi-thelia in vivo. Gene Ther 2000; 7:568-574. Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WR, Finlay D, Barcova M, Cannon PM, Mazurek C, Woodley DT. Restoration of type VII collagen expression and function in dys-trophic epidermolysis bullosa. Nat Genet 2002; 32:1-7. Gusella GL, Fedorova E, Hanss B, Marras D, Klotman ME, Klotman PE. Lentiviral gene transduction of kidney. Hum Gene Ther 2002; 13:407-414.

Delenda C, Audit M, Danos O. Biosafety issues in lentivector production. Curr Top Microbiol Immunol 2002; 261:123-141. Browning O, Schmidt RD, Lew KA, Rizvi TA. Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions. J Virol 2001; 75:5129-5140. Evans JT, Garcia V. Lentivirus vector mobilization and spread by human immunodeficiency virus. Hum Gene Ther 2000; 11: 2331-2339.

Bukovsky AA, Song JP, Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 1999; 73:7087-7092. Noguchi P. Risks and benefits of gene therapy. New Engl J Med 2003; 348:193-194.

Check E. Second cancer case halts gene-therapy trials. Nature 2003; 421:305.

Zaiss AK, Son S, Chang LJ. RNA3' readthrough of oncore-trovirus and lentivirus: Implications for vector safety and efficacy. J Virol 2002; 76:7209-7219.

Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101:2099-2114.

0 0

Post a comment